Examine Initials

PTO/SB/08a (08-03) Approved for use through 07/31/2008, OMB 0851-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known

Substitute folding 449A/R SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

10/815,339 Application Number Filing Date March 31, 2004 First Named Inventor Vilmos KERI et al. 1614 To be assigned Examiner Name

2664/58004

(Use as many sheets as necessary)

US-4,160,861

Sheet of 1

		U.S. PATENT D	OCUMENTS		
	Document Number	Publication Date	Name of Patentee or Applicant	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	Number - Kind Code ² (7 known)	MOH-OD-YYYY	of Clied Document		
_	US- 6,387,258 B1	May 14, 2002	Keri et al.		
	US- 5,200,505	April 06, 1993	Takesako et al.		

Cote et al.

Attorney Docket Number

		FOREIGN	PATENT DOCUMENT	rs		
		Foreign Patent Document			Pages.	
Examin er Initials*	Cits No. ¹ Country Code ³ – Number ⁴ - Kind Code ⁵ (<i>6</i> ' known)	Publication Date MIM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Columns, Lines, Where Relevant Passages or Relevant Figures Appear	7°	
						_

July 10, 1979

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials;	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
A .		Surjit S. Sengha, Fermentation, in Kirk Othmer Encyclopedia of Chemical Technology, Vol. 10, p. 361-381 (Jacquiline I. Kroschwitz, editor. 4th ed. 1993)		
1		The Merck Index, Maryadele J. O'Neil et al. eds., "Pimecrolimus", page 1331, 13th ed. 2001.		
		Martindale: The complete drug reference, Sean C. Sweetman ed., "Sirolimus", page 568, Pharmaceutical Press 33rd ed. 2002		
		C.E.M. Griffiths "Ascomycin: An Advance in the Management of Atopic Dermatitis" British J. of Dermatology, V. 144, p. 679-681, (2001)		
		Martindale: The complete drug reference, Sean C. Sweetman ed., "Everolimus", page 539, Pharmaceutical Press 33rd ed. 2002		
		Zhiguo Song et al. "Highly Chemoselective Trichloracetimidate-Mediated Alkylation of Ascomycin: A Convergent, Practical Synthesis of the Immunosupporessant L-733,725" J. Org. Chem. 1999, v. 64, p. 1859-1867		
		Jun'ichi Kobayashi et al. "Amphidinolides T2, T3, and T4, New 19-Membered Macrolides from the Dinoflagellate Amphidinium sp. and the Biosynthesis of Amphidinolide T1" J. Org. Chem. 2001, v. 66, p. 134-142		
M		K. Yoshii et al. "Liquid Chromatographic Determination of Emamectin, Milbernectin, Ivermeetin and Abamectin in Crops and Confirmation by Liquid Chromatography – Mass Spectrometry" Journal of Chromatography A, y. 896, 2000, p.75-85		

Examiner Signature	M	Date Considered	12/2/86

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. Wind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if

of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 it possible. "Applicant is to place a check mark here it English language Translation is estached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this from endor suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.